Immunostimulatory Tim-1–specific antibody deprograms Tregs and prevents transplant tolerance in mice

Nicolas Degauque, Christophe Mariat, James Kenny, Dong Zhang, Wenda Gao, Minh Diem Vu, Sophoclis Alexopoulos, Mohammed Oukka, Dale T. Umetsu, Rosemarie H. DeKruyff, Vijay Kuchroo, Xin Xiao Zheng, and Terry B. Strom

T cell Ig mucin (Tim) molecules modulate CD4+ T cell responses. In keeping with the view that Tim-1 generates a stimulatory signal for CD4+ T cell activation, we hypothesized that an agonist Tim-1–specific mAb would intensify the CD4+ T cell–dependant allograft response. Unexpectedly, we determined that a particular Tim-1–specific mAb exerted reciprocal effects upon the commitment of alloactivated T cells to regulatory and effector phenotypes. Commitment to the Th1 and Th17 phenotypes was fostered, whereas commitment to the Treg phenotype was hindered. Moreover, ligation of Tim-1 in vitro effectively deprogrammed Tregs and thus produced Tregs unable to control T cell responses. Overall, the effects of the agonist Tim-1–specific mAb on the allograft response stemmed from enhanced expansion and survival of T effector cells; a capacity to deprogram natural Tregs; and inhibition of the conversion of naive CD4+ T cells into Tregs. The reciprocal effects of agonist Tim-1–specific mAbs upon effector T cells and Tregs serve to prevent allogeneic transplant tolerance.

Introduction

T cell Ig mucin (Tim) molecules are structurally related to type I membrane glycoproteins expressed on T cells (1). Polymorphisms within the Tim gene locus are associated with susceptibility to atopy and autoimmunity, which suggests that Tim proteins modulate CD4+ T cell responses (2–4). Indeed, recent reports have confirmed the role of Tim molecules in regulating the expansion and effector function of Th1 and Th2 cells (5–8). For example, Tim-3 and Tim-2 negatively regulate Th1 and Th2 responses, respectively (9, 10), through the delivery of inhibitory or death signals into select CD4+ T cell populations.

Based on genetic linkage and epidemiologic studies, it was reasonable to assume that ligation of Tim-1 might preferentially skew the immune response toward a Th2 phenotype (11, 12), because anti–Tim-1 amplifies Th2-type cytokine production in a Th2-biased experimental model of airway hyperreactivity (13). Unlike ligation of Tim-3 or Tim-2, Tim-1 ligation heightens T cell activation (13). Naive CD4+ T cells upregulate Tim-1 expression early after activation, and Tim-1 cell-surface expression is maintained through differentiation into the Th1 or Th2 phenotype (13, 14). Tim-4, a molecule expressed by DCs (15), is a ligand of Tim-1 (15). Cross-linking of Tim-1 on the surface of T cells in vitro by Tim-4 Ig enhances T cell proliferation and production of Th1 and Th2 cytokines. In vivo administration of Tim-4 Ig during an ongoing immune response creates similar effects (15).

In keeping with the view that Tim-1 generates a stimulatory signal for T cell activation (16), we demonstrate that an agonist anti–Tim-1 mAb (13, 17) intensifies the allograft response and prevents development of T cell tolerance. Unexpectedly, we determined that agonist anti–Tim-1 mAb exerts reciprocal effects upon the commitment of alloactivated T cells to regulatory and effector phenotypes. In the context of alloimmunity, we demonstrate that Tim-1 greatly enhances proinflammatory (Th1 and Th17) cell–mediated responses and hampers the development of peripheral tolerance. In addition, we now report on the capacity of Tim-1 to deprogram the CD4+Foxp3+ T cell–dependent regulatory loops and to promote differentiation of Th17 cells. Collectively, our data indicate that ligation of Tim-1 reciprocally alters commitment of alloreactive CD4+ T cells to the CD4+Foxp3+ and CD4+Th17+ phenotypes.

Results

3B3 anti–Tim-1 mAb strengthens Th1/Th17 polarization and enhances the expansion and survival of CD4+ and CD8+ alloreactive cells in vitro. Umetsu et al. developed the 3B3 agonist type anti–Tim-1 mAb and provided the first mechanistic insights into the function of Tim-1 (13). Application of 3B3 anti–Tim-1 mAb heightens T cell activation and prevents the development of respiratory tract tolerance in a Th2-driven model of asthma (13). We have now used 3B3 anti–Tim-1 mAb to study the role of Tim-1 in the in vivo allograft response, a prototypic Th1 effector T cell–driven (Teff-driven) process, and in vitro, e.g., the mixed lymphocyte reaction (MLR) (Figure 1). Mature allogeneic DCs (i.e., DBA/2 bone marrow–derived CD80+CD40+ DCs) were used to stimulate CFSE-labeled C57BL/6 CD4+CD25− and CD8+CD25− T cells in the presence of 3B3 anti–Tim-1 mAb or an isotype control antibody. The proliferative response of CFSE-stained alloreactive T cells was analyzed by flow cytometry (18) (Figure 1A). The proliferative response of CD4+CD25− and CD8+CD25− T cells in the MLR was accelerated and exaggerated with provision of 3B3 anti–Tim-1 mAb (Figure 1, A and B). In cultures containing anti–Tim-1 mAb, 3–4 discrete
generations of T cell proliferation were detectable as early as day 2 of culture, while proliferation was not yet evident at day 2 in control MLR cultures (Figure 1A). Furthermore, by day 4, the addition of 3B3 anti–Tim-1 mAb to the MLR resulted in a substantial increase in CD4+ and CD8+ T cell accumulation (6.5- and 3.2-fold respectively) as compared with isotype control MLRs (Figure 1B). Detailed analysis of the CFSE profile strongly indicated that the scope of T cell proliferation induced by agonist anti–Tim-1 mAb cannot be restricted to the alloreactive subpopulation (Figure 1A). The proportion of proliferating T cells exceeds any estimation of the frequency of alloreactive T cells. Hence, we tested whether agonist anti–Tim-1 mAb elicited T cell proliferation when syngeneic, not allogeneic, mature DCs are used (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI32562DS1). Surprisingly, anti–Tim-1 mAb elicits robust T cell proliferation in the presence of syngeneic DCs. These data indicate that in the presence of syngeneic DCs, 3B3 anti–Tim-1 mAb acts a polyclonal stimulant.

In order to determine whether anti–Tim-1 mAb might promote the survival of T cells responding in the MLR, we assessed the proportion of cultured T cells programmed for apoptosis by counterstaining CFSE-labeled CD4+ and CD8+ cells with annexin V (Figure 1C). As we have previously reported (19), the intensity of annexin V staining gradually increases with each cell division, reflecting the
physiological process of activation-induced apoptotic cell death. Interestingly, the proportion of proliferating annexin V+CD4+ and CD8+ T cells was markedly reduced in anti–Tim-1 mAb–supplemented MLRs as compared with isotype control–treated cultures (Figure 1C). Hence, expansion of T cells induced by 3B3 anti–Tim-1 mAb in the MLR is due to accelerated and exaggerated cell division as well as a survival advantage directly conferred by Tim-1–dependent signals. In keeping with these observations, amplified expression of the antiapoptotic Bcl-2 gene (20) was detected in MLR-activated, proliferating CD4+ and CD8+ T cells harvested from the anti–Tim-1 mAb–treated cultures (Figure 1D).

Next, we sought to characterize whether supplementation of the MLR with anti–Tim-1 mAb altered the balance of Th1/Th2/Th17 cells. Provision of agonist anti–Tim-1 mAb to the culture enhanced the commitment of proinflammatory Th1 and Th17 T cells, as assessed by intracellular immunostaining for IFN-γ and IL-17 (Figure 1E). These profiles were further confirmed using quantitative real-time PCR (Supplemental Figure 2). In contrast, gene expression for IL-4, the prototypic Th2-type cytokine, was downregulated in cultures supplemented with agonist anti–Tim-1 mAb (Supplemental Figure 2). Thus, activation of the Tim-1 pathway promotes the commitment of naive T cells toward a Th1/Th17-biased proinflammatory-type response.

3B3 anti–Tim-1 mAb dampens expression of regulatory-associated genes and the ability of alloreactive Tregs to suppress Teff responses in vitro. A heightened Th1-type alloreactive response can result from
weakened Treg-dependent T cell immunoregulation. Moreover, a reciprocal relationship between commitment to the Th17 and Treg phenotype has been noted in some settings (21). As 3B3 anti–Tim-1 mAb heightens Th1/Th17 type alloactivation, we sought to determine whether TIM-1–generated signals may impair Treg-dependent immunoregulation.

Interaction of Tregs with highly mature syngeneic DCs rescues Tregs from anergy in vitro (22). We and others have extended this observation to the alloimmune response and have consistently observed substantial proliferation of TCR-transgenic (23) or polyclonal (24) Tregs when MLRs utilize mature allogeneic DCs as stimulator cells. Using this system, we have examined effect of anti–Tim-1 mAb upon the in vitro expansion of alloreactive Tregs (Figure 2).

Proliferation of CD4+CD25+ C57BL/6 Tregs stimulated with mature DBA/2 DCs was markedly enhanced by provision of 3B3 anti–Tim-1 mAb (Figure 2A), suggesting that Tregs to anti–Tim-1 mAb stimulation might amplify the proliferative response of activated Tregs. Thus, we next analyzed transcriptional activation genes in both anti–Tim-1 mAb–treated and control MLRs, focusing specifically on the proliferating (CFSE®) Treg population. We observed that expression of Fox3 transcription factor, the Treg master switch (25), was downregulated in the presence of agonist anti–Tim-1 mAb, whereas Fox3 expression remained high in the isotype control mAb Treg cultures (Figure 2B). Moreover, expression of Fox3–triggered regulatory-associated factors, including CTL–associated antigen–4 (CTLA–4) and glucocorticoid–induced TNF receptor family–related protein (GITR) (25–28), was downregulated after provision of agonist anti–Tim-1 mAb (Figure 2B). In order to exclude the possibility that the increase in cell proliferation resulted from a stimulatory effect of anti–Tim-1 mAb upon a minor population of contaminating CD4+ effector cells, we repeated the MLR with GFP+ Tregs that were directly isolated from Fox3–GFP knock-in mice (21) using a MoFlo cell sorter (purity >98%). A serial analysis on day 2, 4, and 6 revealed that Fox3 gene expression increases markedly from day 2 through day 6 in the isotype control mAb cultures. In contrast, agonist anti–Tim-1 mAb in the MLR serves to powerfully blunt Fox3 gene expression (Figure 2C). This decrease in Fox3 gene expression was strengthened with time (from 34% decrease in gene expression on day 2 to 48% on day 6 in the agonist anti–Tim-1 mAb–supplemented culture vs. isotype control mAb–supplemented culture). The negative influence of anti–Tim-1 mAb on Fox3 expression was confirmed at the protein level (Supplemental Figure 3).

IL–6–/– mice bear a significantly elevated proportion of Fox3+ Tregs. Apparently, an absence of IL–6 favors the generation or expansion of Tregs (29). Xu et al. have shown that provision of exogenous IL–6 induced the differentiation of Fox3+ T cells from CD4+CD25+ Fox3+ T cells (30). To determine whether the downregulation of Fox3 expression induced by agonist anti–Tim-1 mAb is IL–6 dependent, neutralizing anti–IL–6 mAb was added to the culture system (Figure 2D). With provision of neutralizing anti–IL–6 mAb, agonist anti–Tim-1 mAb did not alter the magnitude of Fox3 gene expression.

The function of Tregs harvested from MLRs supplemented with 3B3 anti–Tim-1 mAb or IgG2a control cultures was then tested through their ability to inhibit the proliferative response of CFSE–labeled Teffs to coated anti–CD3 mAb plus soluble anti–CD28 mAb. Consistent with the decrease in Fox3, GITR, CTLA–4, and IL–10 gene expression, the regulatory function of the anti–Tim–1–stimulated Treg population was also markedly impaired (Figure 2E). In comparison to the ability of proliferating Tregs from control MLRs to blunt CD4+ proliferation of Teffs to coated anti–CD3 mAb plus soluble anti–CD28 mAb, the suppressive function of 3B3 anti–Tim–1 mAb–treated alloreactive proliferating Tregs was vastly diminished (Figure 2D). Taken together, the transcriptional profile and functional data suggest that anti–Tim–1 mAb stimulation...
has the unique ability to deprogram Tregs and thereby weaken Treg immunoregulatory function.

Anti–Tim-1 mAb prevents the induction of CD4^+Foxp3^+ Tregs from CD4^+Foxp3^- T cells and promotes the differentiation of Th17 cells. The profound effect of anti–Tim-1 mAb on Foxp3 expression and regulatory functions in natural Tregs prompted us to examine whether anti–Tim-1 mAb would also prevent the induction of Foxp3^+ Tregs from Foxp3^- Teffs. Stimulation of CD4^+GFP(Foxp3^-) T cells in the presence of isotype control mAb and TGF-β induced robust expression of Foxp3 transcripts (Figure 3A) and an increase in the frequency of Foxp3^+CD4^- T cells (~8%–10%) (Figure 3B). It is remarkable that conversion of such inducible Foxp3^+ Tregs from naive CD4^+GFP(Foxp3^-) T cells was completely blocked when anti–Tim-1 mAb was added to the culture (Figure 3, A and B).

Several groups including our own have reported an intriguing reciprocal relation between the development of Tregs and the development of pathogenic effector Th17 cells (21, 31, 32). A common cytokine, TGF-β, is critical for the in vitro development of both Tregs and Th17 cells from CD4^+Foxp3^- T cells. The differentiation into these subsets is determined by the presence or absence of inflammatory cytokines such as IL-6 (21), IL-1α (32), and TNF-α (32). Interestingly, in line with the recent finding that IL-6 in conjunction with TGF-β induces pathogenic Th17 cells while inhibiting the generation of inducible Foxp3^+ Tregs (21) and with the observation that downregulation of Foxp3 expression induced by agonist anti–Tim-1 mAb is IL-6 dependent (Figure 2D), the combination of 3B3 anti–Tim-1 mAb with TGF-β promoted differentiation of Th17 cells as well (Figure 3B).

3B3 anti–Tim-1 mAb negates the tolerance-promoting effect of costimulation blockade in islet transplantation. Peripheral transplant tolerance can be regularly achieved through therapies that curtail the expansion of donor-destructive Teffs while preserving or strengthening donor-directed regulatory networks (33). Given the above data showing a detrimental effect of 3B3 anti–Tim-1 mAb on the balance between cytoprotective Tregs and effector cytopathic Th1/Th17 cells, we anticipated that in vivo administration of 3B3 anti–Tim-1 mAb would counteract the beneficial effects of tolerizing therapies in an allogeneic transplant model. To test this hypothesis, we chose an MHC-mismatched islet transplant model in which long-term survival of allogeneic islets can be achieved through administration of an anti-CD154 mAb (6, 34–36). Using this anti-CD154 mAb, tolerance results from inhibitory effects upon potency of donor-directed Teffs and enhances the suppressive function of donor-directed Tregs (6, 34). Indeed, in this model of MHC-incompatible islet transplantation, the ability of anti-CD154 mAb treatment to prevent allograft rejection was largely negated by administration of anti–Tim-1 mAb (Figure 4; P < 0.01; mean survival time, 29 days in the anti–Tim-1 mAb group vs. indefinite graft survival in the control group).

Discussion In a study of the allograft response, we demonstrate that administration of 3B3 agonist anti–Tim-1 mAb prevents the induction of peripheral-type transplant tolerance by (a) enhancing the commitment and expansion of alloreactive T cells in the Th1/Th17 Teffs; (b) deprogramming natural Tregs at the molecular and functional levels; and (c) inhibiting the conversion of regulatory Foxp3^+ cells from the naive Foxp3^- T cells. In contrast, Ueno et al. show that treatment with an antagonist anti–Tim-1 mAb prolongs survival of heart allograft (37). The antagonist anti–Tim-1 mAb inhibits Teff responses and serves to enhance the potency of donor-reactive regulatory CD4^+CD25^+ T cells. Opposing effects of the same agonist and antagonist anti–Tim-1 mAbs have been also noted in an EAE model (17) in which the agonist anti–Tim-1 mAb increases the severity of EAE, whereas the antagonist anti–Tim-1 mAb inhibits the development of EAE. Differences in the avidity of the binding to the IgV domain of the Tim-1 molecule by the agonist and antagonist anti–Tim-1 mAbs may determine the consequences of Tim-1 ligation. The agonist anti–Tim-1 mAb has avidity 17-fold higher than that of the antagonist anti–Tim-1 mAb (17).

Wan and Flavell have generated a mouse in which endogenous Foxp3 gene expression is attenuated in Tregs (38). Using this strategy, they were able to compare the suppressive functions of Foxp3^lo T cells and Foxp3^hi T cells. They determined that reduced Foxp3 expression by natural Tregs results in diminished immunosuppressive functions (38). We now demonstrate that activation of CD4^+Foxp3^- T cells with an agonist anti–Tim-1 mAb leads to downregulation of Foxp3 expression, at both transcriptional and protein levels, as well as expression of Treg-associated molecules such as CD25, CTLA-4, and GITR (25–28). Activation of Tim-1 on CD4^+Foxp3^- T cells completely abrogates the in vitro suppressive functions of Foxp3^+ T cells, as these anti–Tim-1 mAb–stimulated Foxp3^lo T cells fail to regulate the proliferation of Teffs. Hence, ligation of Tim-1 serves to alter the commitment of Tregs from potent Foxp3^hi to ineffective Foxp3^lo Tregs.

A reciprocal relationship between commitment of naive CD4^+ T cells to the Th17 and Treg phenotypes has been discerned in several settings (21, 29). Depending on the presence or absence of certain proinflammatory cytokines such as IL-6 or IL-21 in the milieu of antigen recognition, TGF-β can support de novo differentiation of Th17 or Tregs (21, 32). We now show that engagement of the Tim-1 cell-surface receptor molecule upon T cells cultured with TGF-β skews the commitment of naive T cells to Th1 and Th17 and away from the Foxp3^lo phenotype. Thus, our results lend further support to the concept of reciprocal commitment to Th17 and Treg phenotype, and we introduce a new means by which the commitment to the Teff and Treg phenotypes is regulated. While previous studies have centered upon the commitment of antigen-stimulated naive T cells, we also demonstrate that the Foxp3^lo T cells are not terminally differentiated. Tim-1 may serve to regulate the reciprocal developmental pathway for the genera-

![Figure 4](http://www.jci.org)
tion and maintenance of pathogenic and protective cells in the immune system. In the allograft response, Tim-1 ligation with an agonist anti–Tim-1 mAb promotes the commitment toward the Th17 and Th1 phenotypes and weakens commitment to the Foxp3hi phenotype. Of special importance is the fact that we have now identified a pathway that negatively regulates Foxp3 expression, even in committed Foxp3+ T cells. It appears important to analyze the consequences, in physiological settings, of engagement of Tim-1 by Tim-4, the Tim-1 ligand that is expressed by selected antigen-presenting cell subsets (15). We hypothesize that interaction between Tim-1+ T cells and Tim-4+ DCs serves to heighten immune response by strengthening effector responses and down-regulating the regulatory networks.

In conclusion, the 3B3 agonist anti–Tim-1 mAb heightens cytotoxic allogeneic responses and blocks the induction of transplant tolerance by: (a) favoring expansion and survival of Th1/Th17 cells; (b) disarming Tregs at the molecular and functional levels; and (c) inhibiting the conversion of Teffs into Tregs. In contrast, treatment with an antagonist anti–Tim-1 mAb aids in the induction of transplant tolerance (37).

Methods

Mice. C57BL/6 (H-2b/CD45.2), B6SJL-PtprcPep3/Boyj (H-2b/CD45.1), and DBA/2 (H-2d) mice were purchased from the Jackson Laboratory. The C57BL/6 Foxp3-GFP knock-in mice have been previously described (21). All mice were housed under standard conditions. All animal studies were approved by Institutional Review Board at Harvard Medical School.

mAbs and reagents. All mAbs were purchased from eBioscience, except the anti–Tim-1 mAb (clone 3B3), which was produced in our laboratory.

Cell preparation. CD4+CD25+ or CD8+CD25− T cells were obtained using negative selection. CD4+CD25− T cells were obtained using the mouse CD4+CD25− Regulatory T Cell Isolation Kit (Miltenyi Biotec). The purity of the T cell subset was greater than 95%. CD4+GFP(Foxp3)+ and CD4+GFP(Foxp3)− cells were sorted using a MoFlo high-speed cell sorter (Dako-Cytomation). Highly mature GM-CSF-derived DCs were obtained as previously described (15, 23).

In vitro MLR. C57BL/6 responder T cells were labeled with CFSE (Molecular Probes; Invitrogen) following the manufacturer’s instructions and plated with stimulator cells in 96-well flat-bottom plates at a ratio of 4:1 in a final volume of 250 μl of complete medium. Complete medium consisted of 1× MEM (Gibco/BRL; Invitrogen) supplemented with 2 mM glutamine, 1 mM Na pyruvate, 0.1 mM nonessential amino acids, 10% FBS, 0.3% Na bicarbonate, 19 mM HEPES, 50 μg/ml gentamicin, 5.5 × 10−5 M 2-mercaptoethanol, and 100 μ/ml penicillin/streptomycin. IgG2a isotype control or anti–Tim-1 mAb was added to the culture medium in a final volume of 2.5 μg/ml. An antagonistic anti–Tim-1 mAb–treated MLRs. Islet allograft survival was analyzed by the Kaplan-Meier test. Graphs represent the mean of the gene expression detected in a set of samples and error bars represent SEM.

Islet transplantation. DBA/2 (H-2d) into C57BL/6 (H-2b) islet transplantation was performed as previously described (39). The tolerance-promoting protocol consisted of 250 μg hamster anti-mouse CD154 (MR1, IgG2a, ATCC HB11048) administered i.p. on days 0 and 2 after transplantation. MR1 anti–CD154 mAb treatment was coadministered with 2 doses (250 μg each) of either rat IgG2a (isotype control) or 3B3 anti–Tim-1 mAb.

Statistics. Mann-Whitney U tests were performed to compare gene-specific transcript levels present in cells harvested from control (IgG2a) and anti–Tim-1 mAb–treated MLRs. Islet allograft survival was analyzed by the Kaplan-Meier test. P values of less than 0.05 were considered significant.

Acknowledgments

This work was supported by grants from the Société de Néphrologie (to C. Mariat), the Société Francophone de Transplantation (to C. Mariat), the National Institute of Allergy and Infectious Disease (to X.X. Zheng, V. Kuchroo, D. Umetsu, and T.B. Strom), and the Juvenile Diabetes Research Foundation Center for Immunologic Tolerance at Harvard Medical School (to T.B. Strom).

Received for publication May 2, 2007, and accepted in revised form November 13, 2007.

Address correspondence to: Terry B. Strom, Transplant Research Center, Beth Israel Deaconess Medical Center, H.I.M.-I., Room 1026, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. Phone: (617) 667-0850; Fax: (617) 667-0923; E-mail: ttstrom@bidmc.harvard.edu.

Nicolas Degaque and Christophe Mariat are co-first authors and contributed equally to this work.


